Sickle Cell Disease: Monitoring, Current Treatment, and Therapeutics Under Development

Carolyn Hoppe; Lynne Neumayr

doi:10.1016/j.hoc.2019.01.014

Sickle Cell Disease: Monitoring, Current Treatment, and Therapeutics Under Development

Hematol Oncol Clin North Am. 2019 Jun;33(3):355-371. doi: 10.1016/j.hoc.2019.01.014. Epub 2019 Mar 28.

Authors

Carolyn Hoppe¹, Lynne Neumayr²

Affiliations

¹ Department of Pediatrics, Division of Hematology/Oncology, UCSF Benioff Children's Hospital Oakland, 747 52nd Street, Oakland, CA 94609, USA. Electronic address: CHoppe@mail.cho.org.
² Department of Pediatrics, Division of Hematology/Oncology, UCSF Benioff Children's Hospital Oakland, 747 52nd Street, Oakland, CA 94609, USA.

PMID: 31030807
DOI: 10.1016/j.hoc.2019.01.014

Abstract

Screening and early detection of organ injury, as well as expanded use of red cell transfusion and hydroxyurea in children have changed best practices for clinical care in sickle cell disease. The current standard of care for children with sickle cell disease is discussed through a review of screening recommendations, disease monitoring, and approach to treatment. Novel pharmacologic agents under investigation in clinical trials are also reviewed.

Keywords: Hydroxyurea; Novel therapeutics; Screening; Sickle cell disease; Treatment.

Publication types

Review

MeSH terms

Anemia, Sickle Cell / blood
Anemia, Sickle Cell / diagnosis
Anemia, Sickle Cell / therapy*
Antisickling Agents / therapeutic use
Child
Clinical Trials as Topic
Erythrocyte Transfusion / methods*
Glutamine / therapeutic use*
Humans
Hydroxyurea / therapeutic use*
Monitoring, Physiologic / methods*
Stem Cell Transplantation / methods*

Substances

Antisickling Agents
Glutamine
Hydroxyurea